Phase 2, Open-Label, Study of Subcutaneous canakinumab, an Anti-IL-1B Human Monoclonal Antibody, for Patients with Low or Int-1 Risk IPSS Myelodysplastic Syndromes including those with clonal cytopenia of undetermined significance.

Disease:

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome

Study phase:

Phase II

Physician name:

Guillermo Garcia-Manero

Department:

Leukemia

For general questions about clinical trials:

1-877-632-6789